Stocktoria

BriaCell Therapeutics Corp. BCTX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2006-10-12 · LEI

BriaCell Therapeutics Corp. statistics & valuation

Market cap$38.5M
P / B2.5×
Return on capital-231.1%

Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202120222023202420252026
Operating margin (%)
202120222023202420252026
Return on equity (%)
-49.90% -259.80% -151.80% -224.30% 202120222023202420252026
Shares outstanding
15.3M 15.5M 16.0M 121907 1.9M 8.7M 202120222023202420252026
Net debt ($)
202120222023202420252026
Share buybacks ($)
202120222023202420252026
Return on assets (%)
-23.80% -63.00% -74.70% -81.60% -121.50% -148.00% 202120222023202420252026
Free cash flow margin (%)
202120222023202420252026
Debt / equity (×)
202120222023202420252026
EPS ($)
-$1.73 -$1.30 -$43.68 -$62.19 -$6.97 202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021
Return on assets-148.0%-121.5%-81.6%-74.7%-63.0%-23.8%
Return on equity-224.3%-151.8%178.5%537.5%-259.8%-49.9%
Current ratio2.765.010.4914.9645.00103.81

Computed from company filings · US · as of 2025-07-31. Facts plus Stocktoria's own computed scores — not investment advice.